Content of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture® [0.03%]
肉毒杆菌毒素美容产品的肉毒神经毒素含量分析：保妥适、 Dysport和Xeomin产品比较
Jürgen Frevert
Jürgen Frevert
Background: Botulinum neurotoxin type A (BoNT/A) is the active substance in preparations used for the highly effective treatment of neurologic disorders such as cervical dystonia, blepharospasm, or spasticity, as well as ...
Comparative Study
Drugs in R&D. 2010;10(2):67-73. DOI:10.2165/11584780-000000000-00000 2010
Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B [0.03%]
贝利尤单抗；贝林利尤姆；LY2127399；BLyS特异性拮抗剂；LY2409884
Belimumab is a fully human monoclonal antibody for the treatment of autoimmune disorders that is being developed by Human Genome Sciences and GlaxoSmithKline. Two pivotal phase III trials in systemic lupus erythematosus have been concluded ...
Dapagliflozin, a selective inhibitor of the sodium glucose co-transporter type 2 (SGLT2) is in development for type 2 diabetes mellitus with Bristol-Myers Squibb and AstraZeneca. It is currently undergoing phase III development worldwide wi...
Fidaxomicin: Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101 [0.03%]
菲达尼辛：Difimicin; Lipiarmycin; OPT 80; OPT-80; PAR 101; PAR-101
Fidaxomicin, an RNA polymerase inhibitor, is being developed by Optimer and Par Pharmaceuticals as a narrow-spectrum antibacterial for the treatment of Clostridium difficile infections. It is currently in phase III development with promisin...
Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381 [0.03%]
达塞曲匹：JTT 705；JTT-705；R 1658；R1658；RG1658；RO 4607381；RO4607381
Roche and Japan Tobacco are in a licensing agreement to develop and commercialize dalcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor to slow or prevent atherosclerosis. This drug is currently in phase III development. This r...
Naltrexone/bupropion: Contrave(R); naltrexone SR/bupropion SR [0.03%]
纳曲酮/布普品：康莱特(Contrave)；纳曲酮缓释片/布普品缓释片
In March 2010, Orexigen(R) Therapeutics submitted a new drug application (NDA) for approval of naltrexone sustained release (SR)/bupropion SR (Contrave(R)) for the treatment of obesity in the US. The tablet contains naltrexone SR 32 mg and ...
John Z Duan
John Z Duan
Background and objective: Drug-drug interaction (DDI) is an important aspect of drug development, especially for safety. When a drug is used concomitantly with other drug(s), one of the major concerns is the change of exp...
Wei Wu
Wei Wu
MicroRNA (miRNA) is an endogenous non-protein coding small RNA molecule that negatively regulates gene expression by the degradation of messenger RNA (mRNA) or the suppression of mRNA translation. miRNA plays important roles in physiologic ...